Home > Insider Trading > Filing (0001209191-18-056013)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1358762	Reata Pharmaceuticals Inc	RETA	Pharmaceutical Preparations (2834)	113651945

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1662394	Wayne Keith Ward	2801 Gateway Drive Suite 150 Irving TX 75063	Chief Development Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Class A Common Stock	Acquisiton	2018-10-23	14,250	$0.00	14,250	No	4	C	Direct
Class A Common Stock	Disposition	2018-10-23	14,250	$57.08	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Class B Common Stock	Employee Stock Option (right to buy)	Disposition	2018-10-23	14,250	$0.00	14,250	$11.62
Class A Common Stock	Class B common stock	Acquisiton	2018-10-23	14,250	$11.62	14,250	$0.00
Class A Common Stock	Class B common stock	Disposition	2018-10-23	14,250	$0.00	14,250	$0.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
34,787	2023-06-15	No	4	M	Direct
14,250		No	4	M	Direct
0		No	4	C	Direct

Footnotes

The exercise, conversion and sale reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2017.
The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions on one day at prices ranging from $56.84 to $57.53, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The options, representing a right to purchase a total of 82,287 shares, vested in twenty equal quarterly installments beginning on September 15, 2013.